Pain, Postoperative
Conditions
Keywords
Postoperative Pain;, Post-Craniotomy, Pre-emptive Scalp Infiltration, Ropivacaine, Triamcinolone Acetonide
Brief summary
Pain is common for the first 2 days after major craniotomy. A majority of patients would suffer from moderate-to-severe postoperative pain after undergoing craniotomy. Inadequate analgesia induced sympathetically mediated hypertension may lead to an increased risk for post-operative complications. Adequate pain control is essential for patients' prognosis and their postoperative life quality. Pain after craniotomy derives from the scalp and pericranial muscles. Local anesthetics administered around the incision have been performed clinically. However, some studies revealed that the analgesic effect of local anesthetics was not unsatisfactory due to its short pain relief duration. Pain is common for the first 2 days after major elective intracranial surgery, and the relatively short analgesic time of scalp infiltration does not seem to meet the requirements of craniotomy. Steroid such as triamcinolone acetonide as an adjuvant to local anesthetics intra-articular injected locally ameliorated pain intensity inarthroscopic knee surgery or total knee arthroplasty. However, there has not been reported about local application of triamcinolone acetonide on scalp infiltration. Thus, the investigators suppose that pre-emptive scalp infiltration with steroid (triamcinolone acetonide) plus local anesthetic (ropivacaine) could relieve postoperative pain after craniotomy in adults.
Interventions
DRUGThe TR group
Miscible liquid of triamcinolone acetonide and ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, 0.25ml triamcinolone acetonide (40mg/ml), plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
DRUGThe R group
Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
Sponsors
Beijing Tiantan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* Patients scheduled for elective craniotomy for resection of tumour under general anaesthesia; * American Society of Anesthesiologists (ASA) physical status of I ,II or III; * Participates with an anticipated fully recovery within 2 hours postoperatively;
Exclusion criteria
* History of craniotomy; * Expected delayed extubation or no plan to extubate; * Participants who cannot use a patient-controlled analgesia (PCA) device; * Participants who cannot understand the instructions of a numeral rating scale (NRS) 35 before surgery; * Extreme body mass index (BMI) (\< 15 or \> 35); * Allergy to opioids, triamcinolone acetonide or ropivacaine; * History of excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks), or use of drugs with confirmed or suspected sedative or analgesic effects; * History of psychiatric disorders, uncontrolled epilepsy or chronic headache; * Pregnant or at breastfeeding; * Symptomatic cardiopulmonary, renal, or liver dysfunction or history of diabetes; * Preoperative Glasgow Coma Scale\< 15; * Suspicion of intracranial hypertension; * Peri-incisional infection; * Participants who have received radiation therapy and chemotherapy preoperatively or with a high probability to require a postoperative radiation therapy and chemotherapy according to the preoperative imaging.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative sufentanil consumption within 48 hours postoperatively | Within 48 hours after the operation | All participates will receive an electronic intravenous patient-controlled analgesia (PCA) device. Participates will be advised to push the analgesic demand button if they feel pain. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The total times that participants press patient-controlled analgesia button | Within 48 hours postoperatively | The total times that participants press patient-controlled analgesia button including effective presses and ineffective presses. |
| Numerical rating scale (NRS) | At 2 hours, 4 hours, 8 hours, 24 hours, 48 hours, 72 hours, 1 week, 2 weeks, 1 month, | Pain will be assessed after surgery by numerical rating scale (0 indicates no pain, 10 indicates the most severe pain imaginable). |
| Postoperative nausea and vomiting | At 2 hours, 4 hours, 8 hours, 24 hours, 48 hours after surgery | Postoperative nausea and vomiting (PONV) was rated by participates as: 0, absent; 1, nausea not requiring treatment; 2, nausea requiring treatment; and 3, vomiting. |
| The first time to press the patient-controlled analgesia button | Within 48 hours after the operation | The first time that the participants press the patient-controlled analgesia button. |
| The total consumption of opioids during the operation | During procedure | The total consumption of opioids during the operation |
| The length of stay | Approximately 2 weeks after the surgery | The duration of hospitalization after the operation |
| Wound Healing Score | At 1 month after surgery | Skin Healing 1: fully healed; 2: ≤3 cm in total not healed; 3: \>3 cm not healed; 4: areas of necrosis ≤3 cm; 5: areas of necrosis \>3 cm Infection 1: none; 2: ≤0.5-cm margin of redness; 3: more redness or superficial pus; 4: deep infection; not applicable Hair Regrowth 1: even regrowth along wound; 2: ≤3 cm not regrowing; 3: \>3-6 cm not regrowing; 4: \>6 cm not regrowing; not applicable |
| The times of emergency reducing blood pressure after the operation | Within 48 hours after the operation | The criteria for treatment is determined by the participant's surgeon in charge.The times of emergency reducing blood pressure will be recording by the investigator. |
Countries
China
Outcome results
None listed